Crescendo Biologics to present at the 2024 AACR Annual Meeting
6 March 2024
Crescendo Biologics to present at the 2024 AACR Annual Meeting View PDF
Read more
Category: Uncategorised
Crescendo Biologics to participate in upcoming investor and partnering conferences
29 February 2024
Crescendo Biologics to participate in upcoming investor and partnering conferences View PDF
Read more
Hello world!
6 July 2020
Crescendo Biologics enters pre-clinical collaboration with Orano Med to explore Targeted Alpha Therapy
Read more
Clinical Development
5 May 2020
Crescendo Biologics and Cancer Research UK sign Clinical Development Partnership to develop CB213, a novel bispecific Humabody® therapeutic
Read more
Crescendo Biologics and Cancer Research UK sign Clinical Development Partnership to develop CB213, a novel bispecific Humabody® therapeutic
5 May 2020
Crescendo Biologics and Cancer Research UK sign Clinical Development Partnership to develop CB213, a novel bispecific Humabody® therapeutic View PDF
Read more
Chief Medical Officer
3 February 2020
Crescendo Biologics appoints Dr Kenji Hashimoto as Chief Medical Officer
Read more
Crescendo Biologics appoints Dr Kenji Hashimoto as Chief Medical Officer
3 February 2020
Crescendo Biologics appoints Dr Kenji Hashimoto as Chief Medical Officer View PDF
Read more
Crescendo Biologics appoints Dr Kenji Hashimoto as Chief Medical Officer
3 February 2020
Crescendo Biologics appoints Dr Kenji Hashimoto as Chief Medical Officer View PDF
Read more
Crescendo Biologics Presenting at Key Industry Events during October 2019
16 October 2019
View PDF
Read more
Crescendo Biologics Reaches Fifth Milestone in its Strategic Collaboration with Takeda
24 September 2019
View PDF
Read more
Crescendo Biologics’ second oncology-targeted Humabody® licensed by Takeda
23 July 2019
View PDF
Read more